Finance

Beta
Lists
EYPT:NASDAQ
EyePoint Inc
$14.40
+0.14%
(+0.020) 1D
$14.40
0.00% (0.00)
After hours
Closed: Jun 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EYPT...
Open
$14.38
High
$14.85
Low
$14.29
Mkt. cap
1.21B
Avg. vol.
1.04M
Volume
895.08K
52-wk high
$19.01
52-wk low
$8.88
EPS
-$3.50
Beta
1.72
Shares outstanding
83.84M
No. of employees
214
Open
$14.38
High
$14.85
Low
$14.29
Mkt. cap
1.21B
Avg. vol.
1.04M
Volume
895.08K
52-wk high
$19.01
52-wk low
$8.88
EPS
-$3.50
Beta
1.72
Shares outstanding
83.84M
No. of employees
214
News stories
From sources across the web
Profile
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery. pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner. In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc. Wikipedia
About EyePoint Inc
CEO-
Employees214
Founded2000
HeadquartersWatertown, Massachusetts, United States
SectorPharmaceutical industry
Websiteeyepoint.bio
Analyst Ratings
Based on 7 analysts giving stock ratings to EYPT in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for EYPT in the last 3 months.
Highest
Current $14.40
$68.00 (+372.22%)
Average
$37.57 (+160.90%)
Lowest
$20.00 (+38.89%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Yatin Suneja
Guggenheim
Buy
Reiterated
$68.00
+372.2%
06/24/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$68.00
+372.2%
06/24/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$36.00
+150%
06/22/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$43.00
+198.6%
06/18/2026
Lisa Walter
RBC Capital
Buy
Maintained
$37.00
+156.9%
05/07/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$30.00
+108.3%
05/07/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$29.00
+101.4%
05/06/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$20.00
+38.9%
05/06/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$33.00
+129.2%
03/10/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$35.00
+143.1%
03/09/2026
Unknown Analyst
Jefferies
Buy
Maintained
$33.00
+129.2%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
5.33M
966.00K
620.00K
696.00K
Cost of goods sold
54.65M
47.46M
58.58M
71.67M
Cost of revenue
54.65M
47.46M
58.58M
71.67M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.91M
15.53M
12.39M
16.26M
Operating expense
12.91M
15.53M
12.39M
16.26M
Total operating expenses
67.56M
62.99M
70.96M
87.92M
Operating income
-62.23M
-62.02M
-70.34M
-87.23M
Other non operating income
-
-
-
-
EBT including unusual items
-59.33M
-59.73M
-67.42M
-84.88M
EBT excluding unusual items
-59.33M
-59.73M
-67.42M
-84.88M
Income tax expense
93.00K
-
186.00K
-50.00K
Effective tax rate
-0.16%
-
-0.28%
0.06%
Other operating expenses
-
-
-
-
Net income
-59.43M
-59.73M
-67.61M
-84.83M
Net profit margin
-1,114.31%
-6,183.44%
-10,904.68%
-12,188.51%
Earnings per share
-0.85
-0.85
-0.81
-0.99
Interest and investment income
2.89M
2.29M
2.96M
2.34M
Interest expense
-
-
-33.00K
-
Net interest expenses
2.89M
2.29M
2.92M
2.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-61.69M
-61.45M
-69.65M
-86.59M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer